$2.07 +0.01 (0.47%)

Phio Pharmaceuticals Corp. Common Stock (PHIO)

Phio Pharmaceuticals Corp. (PHIO) is a biotechnology company that focuses on developing immuno-oncology therapies using its proprietary RNA interference (RNAi) platform. The company aims to enhance the body's immune response to cancer by targeting and modulating specific genes involved in tumor immune evasion.

🚫 Phio Pharmaceuticals Corp. Common Stock does not pay dividends

Company News

Merkel Cell Carcinoma Market Set for Rapid Growth in the Coming 10 Years Across the 7MM | DelveInsight
GlobeNewswire Inc. • Delveinsight • August 20, 2025

The Merkel cell carcinoma market is expected to grow significantly between 2025-2034, driven by rising global incidence, increased awareness, and innovative treatment developments like immunotherapies and targeted therapies.

Phio Posts Wider Loss in Fiscal Q2
The Motley Fool • Jesterai • August 14, 2025

Phio Pharmaceuticals reported a Q2 2025 net loss of $2.2 million, with its lead candidate PH-762 showing promising early clinical results in cancer therapy. The company's INTASYL platform demonstrated positive safety and efficacy signals in gene-silencing cancer treatments.

Why Nxu Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket
Benzinga • Avi Kapoor • December 14, 2023

Shares of Nxu, Inc. (NASDAQ: NXU) rose sharply in pre-market trading after the company signed a letter of intent outlining investment in Lynx Motors. Nxu, shares rose 42.1% to $0.0278 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers XBP Europe Holdings, Inc. (NASDAQ: XBP) shares rose 150% to $14.20 in pre-market trading after declining around 20% on Wednesday. Hanryu Holdings, Inc. (NASDAQ: HRYU) gained 34.8% to $1.47 in pre-market trading after jumping 28% on Wednesday. Meiwu Technology Company Limited (NASDAQ: WNW) shares gained 21.1% to $0.0850 in pre-market trading. Codexis, Inc. (NASDAQ: CDXS) shares surged 20.5% to $2.52 in pre-market trading. Codexis announced achievement of gram-scale synthesis with its ECO Synthesis platform. Esperion Therapeutics, Inc. (NASDAQ: ESPR) shares climbed 15.2% to $1.74 in pre-market trading. Esperion said that the FDA updated LDL-C lowering indication for NEXLETOL (bempedoic acid) tablet and NEXLIZET (bempedoic acid and ezetimibe) tablet. Blue Water Biotech, Inc. (NASDAQ: BWV) shares rose 14.9% to $0.3109 in pre-market trading after gaining ...

Penny Stocks To Buy Now? 5 Under $5 To Watch This Week
PennyStocks • J. Samuel • December 5, 2023

Penny stocks to buy? Here are some of the most active under $5 to watch. The post Penny Stocks To Buy Now? 5 Under $5 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

PHIO Jumps 91% on Encouraging Preclinical Cancer Drug Data
Zacks Investment Research • Zacks Equity Research • October 12, 2023

Data from preclinical studies show that Phio's (PHIO) cancer drug PH-894 is effective in BRD4 inhibition for treating various cancer indications like melanoma, breast cancer and lung cancer.